Clinical trial · Interventional
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma
NCT00582166CI-TRIAL-00042253terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): See 'Limitations and Caveats' section
Summary
Brief summary (as posted)
Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ibritumomab Tiuxetan (Zevalin) + Rituximab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance
- interventionNames
- Drug: Ibritumomab Tiuxetan (Zevalin) + Rituximab
Primary outcomes (1)
- measure
- Median Progression Free Survival (PFS)
- timeFrame
- up to 5 years, 9.5 months, from first day on treatment to last follow up
- description
- Estimate median progression free survival (PFS), where PFS is defined as the number of days from administration of Ibritumomab tiuxetan In111 (defined as day 1) until the participant develops progressive disease or death from NHL (Non-Hodgkin's Lymphoma).
Secondary outcomes (4)
- measure
- 24-month Progression Free Survival (PFS)
- timeFrame
- Up to 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with biopsy-proven non-hodgkins lymphoma of follicular grade 1, 2, or 3 * Meeting FLIPI criteria for intermediate or high risk. * No prior chemotherapy, radiotherapy or immunotherapy for lymphoma; * Patients may not have known HIV infection, and must not be Hepatitis B Surface Antigen positive. Exclusion Criteria: * May not be pregnant or breastfeeding, have documented CNS (Central Nervous System) disease, G-CSF (Granulocyte Colony Stimulating Facto) or GM-CSF (Granulocyte/Macrophage Colony Stimulating Factor) within 2 weeks prior
References
Publications (0)
Data not yet available
No reference posted for this study.